San Diego, CA — August 12, 2025 — Leads & Copy — Endure Biotherapeutics Inc. has received a Phase I Small Business Innovation Research grant from the National Cancer Institute to advance its Engineered Native Bacteria therapy for Familial Adenomatous Polyposis. The funding will support the development of a novel ENB candidate for the treatment of FAP, a rare genetic disorder that leads to the growth of colon and rectal polyps, with nearly all affected individuals progressing to colorectal cancer by age 40 if left untreated.
“We are deeply grateful for the NCI’s support and recognition of our ENB platform technology,” said Dr. Amir Zarrinpar, founder and Chief Medical Officer of Endure Bio.
Endure Bio’s ENB platform modifies bacteria isolated from human hosts to treat disease, while retaining their natural ability to engraft and persist in the gut.
The company is advancing a pipeline of ENB-based therapeutics targeting both rare and widespread chronic diseases, including FAP, PKU, and age-related metabolic disorders to promote healthy longevity.
For more information, visit endurebio.com.
Contact: info@endurebio.com
